Skip to main content

Main menu

  • Home
  • Current Issue
  • Archive
  • Info for
    • Authors
    • Subscribers
    • Advertisers
    • Editorial Board
  • Other Publications
    • In Vivo
    • Cancer Genomics & Proteomics
    • Cancer Diagnosis & Prognosis
  • More
    • IIAR
    • Conferences
    • 2008 Nobel Laureates
  • About Us
    • General Policy
    • Contact
  • Other Publications
    • Anticancer Research
    • In Vivo
    • Cancer Genomics & Proteomics

User menu

  • Register
  • Subscribe
  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Anticancer Research
  • Other Publications
    • Anticancer Research
    • In Vivo
    • Cancer Genomics & Proteomics
  • Register
  • Subscribe
  • My alerts
  • Log in
  • My Cart
Anticancer Research

Advanced Search

  • Home
  • Current Issue
  • Archive
  • Info for
    • Authors
    • Subscribers
    • Advertisers
    • Editorial Board
  • Other Publications
    • In Vivo
    • Cancer Genomics & Proteomics
    • Cancer Diagnosis & Prognosis
  • More
    • IIAR
    • Conferences
    • 2008 Nobel Laureates
  • About Us
    • General Policy
    • Contact
  • Visit us on Facebook
  • Follow us on Linkedin
Research ArticleClinical Studies

Surgical Treatment for Pulmonary Metastasis of Pancreatic Ductal Adenocarcinoma: Study of 12 Cases

MOTOAKI YASUKAWA, TAKESHI KAWAGUCHI, NORIKAZU KAWAI, TAKASHI TOJO and SHIGEKI TANIGUCHI
Anticancer Research October 2017, 37 (10) 5573-5576;
MOTOAKI YASUKAWA
Department of Thoracic and Cardiovascular Surgery, Nara Medical University School of Medicine, Kashihara, Japan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: myasukawa@naramed-u.ac.jp
TAKESHI KAWAGUCHI
Department of Thoracic and Cardiovascular Surgery, Nara Medical University School of Medicine, Kashihara, Japan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
NORIKAZU KAWAI
Department of Thoracic and Cardiovascular Surgery, Nara Medical University School of Medicine, Kashihara, Japan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
TAKASHI TOJO
Department of Thoracic and Cardiovascular Surgery, Nara Medical University School of Medicine, Kashihara, Japan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
SHIGEKI TANIGUCHI
Department of Thoracic and Cardiovascular Surgery, Nara Medical University School of Medicine, Kashihara, Japan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Info & Metrics
  • PDF
Loading

Abstract

Background/Aim: Few studies have reported results with pulmonary metastasectomy for pancreatic ductal adenocarcinoma (PDAC), probably because of their extremely poor outcomes. The aim of this study was to review our institutional experience and analyze the outcomes of pulmonary metastasectomy for PDAC. Patients and Methods: A retrospective case-control study of patients undergoing pulmonary metastasectomy for isolated lung metastasis of PDAC between 2004 and 2016. Clinicopathological features were analyzed and survival curves were plotted using the Kaplan–Meier method. Results: Twelve patients were included. The median follow-up period after metastasectomy was 33 months. At the time of analysis, five patients had deceased, two were alive with disease, and five were alive without disease. The median survival time after pulmonary metastasectomy was 47 months. The estimated 3- and 5-year overall survival rates were 62.3% (95%CI=27.8-84.0) and 31.2% (95%CI=1.7-71.7). Conclusion: Outcomes were favorable following pulmonary metastasectomy in selected patients with PDAC.

  • Pulmonary metastasectomy
  • pancreatic ductal adenocarcinoma
  • prognosis

Pancreatic ductal adenocarcinoma (PDAC) is a highly aggressive malignancy. The American Cancer Society estimated approximately 48,960 patients diagnosed with PDAC in 2015, with more than 40,560 deaths attributable to the disease (1). The median 5-year survival of 6% is likely a result of the tumor's invasiveness and propensity toward metastasis (2). Once PDAC has metastasized to distant organs, the prognosis is dismal with an overall 5-year survival of only 1% (3, 4).

Pulmonary metastasectomy has been shown to provide a survival benefit for colorectal cancer patients with pulmonary metastases (5). And recently, Karagkiouzis et al. (6) reported that combined surgical resection of primary non-small cell lung cancer and solitary hematogenous metastasis might be associated with improved survival. Recurrent PDAC, in comparison, has been notoriously difficult to manage surgically as it is typically characterized by aggressive growth, a multifocal pattern of recurrence, and technically unresectable disease (7). Therefore, although the lung is one of the common sites for distant metastasis in PDAC patients (8), the number of reports of pulmonary metastasis of pancreatic cancer is limited. Recently, Arnaoutakis et al. (9) reported the results of nine patients and Tagawa et al. (10) reported the results of four patients who underwent pulmonary metastasectomy for PDAC. Herein, we retrospectively review our institutional experience and analyze the outcomes of 12 patients who underwent surgery for pulmonary metastases of PDAC. To the best of our knowledge, this is the largest case-control study size reported.

Patients and Methods

This study evaluated 12 patients who underwent surgical treatment for pulmonary metastasis of pancreatic cancer and were then histologically diagnosed with PDAC between January 2004 and December 2016 at our institute. The pulmonary metastases were isolated without evidence of other sites of disease recurrence at the time of metastasectomy. The exclusion criteria for entry to the study were complications from other malignant diseases after enrollment. Thus, the lungs represented the first recurrence site of metastasis in this study. Data were collected from patient's medical charts, operative notes and pathologic examination records. Follow-up data were gathered from outpatient clinic records.

Because individual patients were not identified in this retrospective study, the Ethics Review Board of our institute waived the requirement to obtain written informed consent from patients and approved the study protocol.

We used the VATS technique to resect pulmonary metastases. Fortunately, there was no need for conversion to open thoracotomy for any patient in this series.

View this table:
  • View inline
  • View popup
  • Download powerpoint
Table I.

Details of 12 patients.

Follow-up examinations were symptom oriented, but all patients received medical checkups and chest X-rays at least twice a year, while whole-body computed tomography (CT) scans were performed at least once a year.

The disease-free interval (DFI) was defined as the period between curative primary site resection or complete remission and the first detection of pulmonary nodules. Survival curves were plotted using the Kaplan–Meier method. All analyses were conducted using EZR on R commander, version 1.33 (R Foundation for Statistical Computing, Saitama, Japan).

Results

A total of 12 patients were included. The median follow-up period after metastasectomy was 33 months (range=6-72 months). Table I shows the clinicopathological characteristics of the patients. Six patients were male and six were female. The average age on undergoing pulmonary metastasectomy was 74.25 years (range=63-83 years). Six patients had received induction chemoradiotherapy before primary pancreas surgery. The primary tumor had been completely resected in 11 patients, all of whom received chemotherapy after surgery. However, one patient had been inoperable at the primary site upon the first medical examination and received chemoradiotherapy until complete remission. In all 12 patients, there was no recurrence until the pulmonary metastases were revealed. All patients achieved complete resection, with no postoperative deaths or complications, and all received chemotherapy after the pulmonary metastasectomy.

At the time of analysis five patients had deceased, two patients were alive with disease, and five patients were alive without disease. The median survival time after pulmonary metastasectomy was 47 months (range=6-66 months). The estimated 3-year and 5-year overall survival rates were 62.3% (95% confidence interval (CI) 27.8-84.0) and 31.2% (95%CI=1.7-71.7) (Figure 1). The median survival time after primary site surgery or complete remission was 121 months, and the estimated 5-year overall survival was 82.5% (95%CI=46.1-95.3) (Figure 2).

Discussion

Metastasectomy is considered a beneficial treatment for patients with pulmonary metastases whose primary tumor has been well controlled, and pulmonary resection has been shown to be beneficial for patients with resectable and isolated pulmonary metastases (6). However, few studies have reported such results for pulmonary metastasectomy for PDAC, probably because of their extremely poor outcomes. Among long-term survivors after pancreas resection for PDAC, the most common site for disease recurrence is the lung (11).

Arnaoutakis et al. (9) reported the results of nine patients who underwent pulmonary metastasectomy for PDAC. They showed that pulmonary metastasectomy can be performed smoothly and may be a beneficial procedure, and reported median overall survival from pancreatectomy of 51 months in patients who underwent metastasectomy and 23 months in those who had pulmonary metastasis but did not undergo metastasectomy. Moreover, the median survival after relapse was 18.6 months (95%CI=5.6-29.2) for the pulmonary metastasectomy group and 7.5 months (95%CI=3.4-22) for the control group. Our results compare favorably with these findings, the median overall survival from pancreatectomy being 121 months and the median survival after relapse 47 months.

Figure 1.
  • Download figure
  • Open in new tab
  • Download powerpoint
Figure 1.

Overall survival of 12 patients after pulmonary metastasectomy. The median survival time was 47 months and the 5-year survival was 31.2%.

It should be emphasized that this is a highly selected group of patients who developed metachronous isolated pulmonary metastasis following pancreatic resection. A relatively long interval between initial resection of primary pancreatic cancer and relapse, isolated and stable disease over time, and favorable response to systemic therapy were considered indicative of favorable pathology and a requisite to be considered for pulmonary metastasectomy.

Katz et al. (11) reported that the median overall survival was significantly longer for patients with isolated pulmonary recurrence (40.3 months) than with other metastases (20.9 months; hazard ratio 5.85, p=0.0156). Thomas et al. (7) reported their experience with 21 selective resections of solitary metastases, including seven lung metastases. Among patients who underwent reoperation, overall survival was significantly longer in those with a median first DFI of >20 months than in those with a first DFI of <20 months (p=0.033).

All patients in the present study had isolated pulmonary recurrence at first relapse. Of the three patients who had a first DFI of <20 months, two deceased before the end of the observation period.

Selected patients with isolated pulmonary recurrence of PDAC after a prolonged DFI are good candidates to achieve a favorable prognosis through pulmonary metastasectomy. Although the lung is a major site of recurrence in PDAC, there are not many patients who have only a solitary lung metastasis. And so, it remains unclear why some patients have only a solitary lung metastasis and why patients with metastasis to the lung as their first site of recurrence have a better prognosis. The animal models are very useful for cancer investigation. In an experimental lung-metastasis model of nude mice, Tome et al. (12) reported that tumor emboli were observed in pulmonary vessels and invading cancer cells were observed at the margin of tumor emboli eight weeks after cancer-cell implantation into the tibia. Sundaram et al. (13) reported that high-fat diet significantly increased the number of lung metastases due to the increase of the abundance of proinflammatory cytokines and angiogenic factors in plasma and tumors. There might be some differences between solitary lung metastasis and not concerning cancer-cell adaptation to the pulmonary microenvironment and tumor progression of pulmonary metastasis.

Figure 2.
  • Download figure
  • Open in new tab
  • Download powerpoint
Figure 2.

Overall survival of 12 patients after primary-site surgery or complete remission was 121 months and the estimated 5-year overall survival was 82.5%.

There are two main limitations to this study, namely its retrospective design and small sample size. More specifically, the patients in this study are highly selected and have good biological tumor characteristics identified by a favorable response to systemic therapy, and our patients undergoing pulmonary metastasectomy had a relatively long interval between initial pancreatectomy and pulmonary relapse.

Conclusion

We report favorable outcomes following pulmonary metastasectomy in patients who had undergone pancreatic resection for PDAC, although for this small retrospective series we acknowledge the aforementioned limitations. A study involving a large, multi-institutional cohort will be important to validate these findings. Further investigation is required to determine which patients would be best suited for these interventions.

Footnotes

  • This article is freely accessible online.

  • Conflicts of Interest

    The Authors declare that they have no conflict of interest in regard to this study.

  • Received August 8, 2017.
  • Revision received August 26, 2017.
  • Accepted August 28, 2017.
  • Copyright© 2017, International Institute of Anticancer Research (Dr. George J. Delinasios), All rights reserved

References

  1. ↵
    1. Siegal RL,
    2. Miller KD,
    3. Jemal A
    : Cancer statistics, 2015. CA Cancer J Clin 65: 5-29, 2015.
    OpenUrlCrossRefPubMed
  2. ↵
    1. DeSantis CE,
    2. Lin CC,
    3. Mariotto AB,
    4. Siegel KD,
    5. Kramer JL,
    6. Alteri R,
    7. Robbins AS,
    8. Jemal A
    : Cancer treatment and survivorship statistics, 2014. CA Cancer J Clin 64: 252-271, 2014.
    OpenUrlCrossRefPubMed
  3. ↵
    1. Lillemoe KD,
    2. Kaushal S,
    3. Cameron JL,
    4. Sohn TA,
    5. Pitt HA,
    6. Yeo CJ
    : Distal pancreatectomy: indications and outcomes in 235 patients. Ann Surg 229: 693-698, 1999.
    OpenUrlCrossRefPubMed
  4. ↵
    1. Yeo CJ,
    2. Abrams RA,
    3. Grochow LB,
    4. Sohn TA,
    5. Ord SE,
    6. Hruban RH,
    7. Zahurak ML,
    8. Dooley WC,
    9. Coleman J,
    10. Sauter PK,
    11. Pitt HA,
    12. Lillemoe KD,
    13. Cameron JL
    : Pancreaticoduodenectomy for pancreatic adenocarcinoma: postoperative adjuvant chemo-radiation improves survival. A prospective, single-institution experience. Ann Surg 225: 621-633, 1997.
    OpenUrlCrossRefPubMed
  5. ↵
    1. Lumachi F,
    2. Chiara GB,
    3. Tozzoli R,
    4. Del Conte A,
    5. Basso SM
    : Factors affecting survival in patients with lung metastases from colorectal cancer. A short meta-analysis. Anticancer Res 36: 13-19, 2016.
    OpenUrlAbstract/FREE Full Text
  6. ↵
    1. Karagkiouzis G,
    2. Spartalis E,
    3. Moris D,
    4. Patsouras D,
    5. Athanasiou A,
    6. Karathanasis I,
    7. Verveniotis A,
    8. Konstantinou F,
    9. Kouerinis IA,
    10. Potaris K,
    11. Dimitroulis D,
    12. Tomos P
    : Surgical management of non-small cell lung cancer with solitary hematogenous metastases. In Vivo 31: 451-454, 2017.
    OpenUrlAbstract/FREE Full Text
  7. ↵
    1. Thomas RM,
    2. Truty MJ,
    3. Nogueras-Gonzalez GM,
    4. Fleming JB,
    5. Vauther JN,
    6. Pisters PW,
    7. Lee JE,
    8. Rice DC,
    9. Hofstetter WL,
    10. Wolff RA,
    11. Varadhachary GR,
    12. Wang H,
    13. Katz MH
    : Selective reoperation for locally recurrent or metastatic pancreatic ductal adenocarcinoma following primary pancreatic resection. J Gastrointest Surg 16: 1696-1704, 2012.
    OpenUrlPubMed
  8. ↵
    1. Embuscado EE,
    2. Laheru D,
    3. Ricci F,
    4. Yun KJ,
    5. de Boom Witzel S,
    6. Seigel A,
    7. Flickinger K,
    8. Hidalgo M,
    9. Bova GA,
    10. Lacobuzio-Donahue CA
    : Immortalizing the complexity of cancer metastasis: genetic features of lethal metastatic pancreatic cancer obtained from rapid autopsy. Cancer Biol Ther 4: 548-554, 2005.
    OpenUrlCrossRefPubMed
  9. ↵
    1. Arnaoutakis GJ,
    2. Rangachari D,
    3. Laheru DA,
    4. Iacobuzio-Donahue CA,
    5. Hruban RH,
    6. Edil BH,
    7. Pawlik TM,
    8. Schulick RD,
    9. Cameron JL,
    10. Meneshian A,
    11. Yang SC,
    12. Wolfgang CL
    : Pulmonary resection for isolated pancreatic adenocarcinoma metastasis: an analysis of outcomes and survival. J Gastrointest Surg 15: 1611-1617, 2011.
    OpenUrlCrossRefPubMed
  10. ↵
    1. Tagawa T,
    2. Ito K,
    3. Fukuzawa K,
    4. Okamoto T,
    5. Yoshimura A,
    6. Kawasaki T,
    7. Masuda T,
    8. Iwaki K,
    9. Terashi T,
    10. Okamoto M,
    11. Shiromizu A,
    12. Motohiro A,
    13. Maehara Y
    : Surgical resection for pulmonary metastasis from pancreatic and biliary tract cancer. Anticancer Res 37: 1413-1416, 2017.
    OpenUrlAbstract/FREE Full Text
  11. ↵
    1. Katz MH,
    2. Wang H,
    3. Fleming JB,
    4. Sun CC,
    5. Hwang RF,
    6. Wolff RA,
    7. Varadhachary G,
    8. Abbruzzese JL,
    9. crane CH,
    10. Krishnan S,
    11. Vauthey JN,
    12. Abdalla EK,
    13. Lee JE,
    14. Pisters PW,
    15. Evans DB
    : Long-term survival after multidisciplinary management of resected pancreatic adenocarcinoma. Ann Surg Oncol 16: 836-847, 2009.
    OpenUrlCrossRefPubMed
  12. ↵
    1. Tome Y,
    2. Yano S,
    3. Sugimoto N,
    4. Mii S,
    5. Uehara F,
    6. Miwa S,
    7. Bouvet M,
    8. Tsuchiya H,
    9. Kanaya F,
    10. Hoffman RM
    : Use of αv integrin linked to green fluorescent protein in osteosarcoma cells and confocal microscopy to image molecular dynamics during lung metastasis in nude mice. Anticancer Res 36: 3811-3816, 2016.
    OpenUrlAbstract/FREE Full Text
  13. ↵
    1. Sundaram S,
    2. Yan L
    : High-fat diet enhances mammary tumorigenesis and pulmonary metastasis and alters inflammatory and angiogenic profiles in MMTV-PyMT mice. Anticancer Res 36: 6279-6288, 2016.
    OpenUrlAbstract/FREE Full Text
View Abstract
PreviousNext
Back to top

In this issue

Anticancer Research: 37 (10)
Anticancer Research
Vol. 37, Issue 10
October 2017
  • Table of Contents
  • Table of Contents (PDF)
  • Index by author
  • Back Matter (PDF)
  • Ed Board (PDF)
  • Front Matter (PDF)
Print
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word on Anticancer Research.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Surgical Treatment for Pulmonary Metastasis of Pancreatic Ductal Adenocarcinoma: Study of 12 Cases
(Your Name) has sent you a message from Anticancer Research
(Your Name) thought you would like to see the Anticancer Research web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
5 + 11 =
Solve this simple math problem and enter the result. E.g. for 1+3, enter 4.
Citation Tools
Surgical Treatment for Pulmonary Metastasis of Pancreatic Ductal Adenocarcinoma: Study of 12 Cases
MOTOAKI YASUKAWA, TAKESHI KAWAGUCHI, NORIKAZU KAWAI, TAKASHI TOJO, SHIGEKI TANIGUCHI
Anticancer Research Oct 2017, 37 (10) 5573-5576;

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Reprints and Permissions
Share
Surgical Treatment for Pulmonary Metastasis of Pancreatic Ductal Adenocarcinoma: Study of 12 Cases
MOTOAKI YASUKAWA, TAKESHI KAWAGUCHI, NORIKAZU KAWAI, TAKASHI TOJO, SHIGEKI TANIGUCHI
Anticancer Research Oct 2017, 37 (10) 5573-5576;
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Abstract
    • Patients and Methods
    • Results
    • Discussion
    • Conclusion
    • Footnotes
    • References
  • Figures & Data
  • Info & Metrics
  • PDF

Related Articles

  • No related articles found.
  • PubMed
  • Google Scholar

Cited By...

  • No citing articles found.
  • Google Scholar

More in this TOC Section

  • Retrospective Study of Radiotherapy Impact on the Outcome of Material-assisted Implant-based Subpectoral Breast Reconstruction
  • Carbon-ion Radiotherapy for Oligometastatic Colorectal Cancer in the Liver or Lung
  • Treatment Volume, Dose Prescription and Delivery Techniques for Dose-intensification in Rectal Cancer: A National Survey
Show more Clinical Studies

Similar Articles

Keywords

  • Pulmonary metastasectomy
  • pancreatic ductal adenocarcinoma
  • prognosis
Anticancer Research

© 2021 Anticancer Research

Powered by HighWire